Abstract
Background Major depressive disorder (MDD) is considered to be a neuroimmune disorder. However, there are no data regarding the association between comprehensive immune profiles and their interactions with the metabolic syndrome (MetS) in predicting neuroticism, suicidal behaviors, and severity of outpatient MDD (OMDD).
Methods We assayed 48 serum cytokines, chemokines, and growth factors using a multiplex assay in 67 healthy controls and 66 OMDD patients. Around 50% of the OMDD and control participants had a diagnosis of MetS.
Results Ten differentially expressed proteins (DEPs) were upregulated in OMDD (i.e., CXCL12, TNFB, PDGF, CCL11, IL9, IL4, CCL5, CCL2, CCL4, IL1RN), indicating an immune, defense and stress response. Six DEPs were downregulated (VEGFA, IL12, CCL3, CSF1, IL1B, NGF), indicating lowered neurogenesis and regulation of neuron death. Significant interactions between OMDD and MetS caused a) substantial increases in TNF signaling, and upregulation of IL4, IL17, TNF, TNFB, CCL2, CCL5, PDGF, IL1RN; and b) downregulation of VEGFA and FGF. A large part of the variance in neuroticism (26.6%), suicidal behaviors (23.6%), and the MDD phenome (31.4%) was predicted by immunological data and interactions between MetS and CCL5, TNFB or VEGFA.
Discussion OMDD is characterized by an immunoneurotoxic profile which partly explains neuroticism, suicidal behaviors, and the phenome’s severity. Lowered IL-10 and increased neurotoxicity are characteristics of OMDD and other depression phenotypes, including severe first-episode inpatient MDD. The presence of MetS in OMDD considerably exacerbates immunoneurotoxicity. Consequently, immune studies in MDD should always be performed in subjects with and without MetS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ratchadapiseksompotch Fund Graduate Affairs Faculty of Medicine Chulalongkorn University (Grant number GA64/21) a grant from the Graduate School and H.M. the King Bhumibhol Adulyadejs 72nd Birthday Anniversary Scholarship Chulalongkorn University and the 100th Anniversary Chulalongkom University Fund for Doctoral Scholarship to KJ.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research project (#445/63) was approved by the Institutional Review Board of Chulalongkorn University's institutional ethics board. All patients and controls gave written informed consent prior to participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
